With evidence increasingly suggesting a contribution from gut microbiome as an environmental factor contributing to NAFLD and NASH progression, the potential for the discovery of new therapeutic targets for the treatment and prevention of NASH within the gut-microbiota is becoming an increasingly probable outcome.
Attend this workshop to:
• Understand the involvement of endogenously synthesized antibiotics and secondary bile acids in the regulation of the structure of the gut microbiome
• Objectively assess associations, mechanisms and clinical implications of the gut microbiota to fatty liver pathogenesis, including whether a shift in gut microbiome influences the progression from NAFLD to NASH to Cirrhosis to Hepatocellular Carcinoma
• Explore the current understanding of the gut-brain axis in NASH
• Evaluate the potential for microbiome-targeting NASH therapeutics as a preventative and targeted treatment and prevention of NAFLD and NASH
• Impartially hypothesize the potential for a microbiome diagnostic biomarker as preventative intervention against fatty liver disease
Shirly Pinto, Head of Biology & Drug Discovery, Kallyope
Phillip Hylemon, Professor of Microbiology & Medicine, Virginia Commonwealth University
Jasmohan Bajaj, Associate Professor, Division of Gastroenterology, Virginia Commonwealth University
Despite a plethora of animal models in the NASH drug development landscape, preclinical representation of the extent of NASH fibrosis alongside a physiology that accurately replicates human clinical NASH features remains a challenge restricting translation into the clinic.
Join your peers at this workshop to:
• Objectively review advantages and disadvantages of traditional to next-generation rodent models including diet, genetic and chemical models
• Evaluate progression towards animal models that most accurately reflect human NASH fibrosis
• Explore opportunities in non-human primate animals to better recapitulate human clinical features
• Learn of advancements in manipulating animal models to provide more context to preclinical findings
Bryan Fuchs, Assistant Professor of Surgery, Harvard Medical School
Although NASH is very common, recruitment into clinical studies is difficult with high screen fail rate. The opportunity to diagnose and monitor patients non-invasively in combination with an increased awareness of NASH as a sequel of other metabolic disease provides opportunity to overcome this challenge.
Attend this workshop to:
• Examine and overcome barriers in patient recruitment
• Discuss the use of multiple/different endpoints in clinical studies to improve patient recruitment and completion
• Recognise NAFLD/NASH as a public health problem and address potential population interventions
Ravi Ravinuthala, Director, Liver Clinic, Ohio GI
Despite significant progression of established NASH candidates into the clinic, the intricacies of cell-to-cell interactions driving NASH clinical features remains a consistently evolving topic of interest for de novo target identification and disease interventions in the future disease interventions in the future.
Join the in-depth discussion at this workshop to:
• Review of known cell-to-cell interactions implicated in NASH pathogenesis including cross-talk between liver immune cell populations
• Assess the potential for of newly understood cellular interactions as therapeutic targets
• Understand the involvement of cell-to-cell interactions in subset NASH populations to influence stratifying patients for specific NASH treatment patients for NASH treatment
• Evaluate the future of next generation targets for NASH
Ray Chung, Vice Chief of Gastrointestinal Division, Director of Hepatology & Liver Centre, Massachusetts General Hospital
With NASH affecting an estimated 16-30 million adults in the US there is urgent clinical need for reliable methods to diagnose and stage liver pathology using non-invasive biomarkers.
Be part of the conversation at this workshops to:
• Objectively assess the current preclinical non-invasive biomarker landscape and validation of biomarkers
• Evaluate translatable fibrotic endpoints in animal models
• Review the potential of current biomarkers and their data in NASH cohorts
• Discuss biomarkers as a tool in patient diagnosis, stratification and longitudinal monitoring in clinical trials
Saurabh Gupta, Director, Translational Research & Early Clinical, Takeda
With no FDA approved treatments and NASH growing in status as ‘the Next Big Global Epidemic’ analysts forecast that by 2025 the market for NASH treatments could reach $40 billion.
Join this discussion led workshop to:
• Comprehensively review of the main challenges in bringing a NASH drug to market
• Learn of the financial opportunities in NASH drug development
David Lomb, Consultant, Defined Health